Sponsored Webinar: Hope for Critically Ill COVID-19 Patients: Pathogen Hemofiltration - Latest Data & Clinical Experience: Part II
Sponsored by ExThera Medical
Throughout the COVID-19 pandemic, therapy options—like monoclonal antibody/antiviral medications and mechanical ventilation—have been limited for critically-ill COVID-19 patients. But a new therapy, Seraph 100, is now available. Learn about the impact of viremia, innovations in pathogen removal with this commercially available therapeutic, the latest supporting data and literature, and ongoing clinical research demonstrating the clinical and economic benefits of this therapeutic to a broader septic patient population during this sponsored session. Additionally, hear candid commentary from a Seraph 100 user concerning patient identification, timing of initiation, and best practices learned via experience in the ICU, followed by open Q&A.
This course was originally recorded on 11/2/21.
Nurses, Advanced Practice Providers, Physicians, Emergency Responders, Pharmacists, Medical Technologists, Respiratory Therapists, Physical/ Occupational Therapist, Social Workers, Mental Health Professionals, Students, IT Professionals, Sepsis Survivors, Advocates, and more!
Sepsis Alliance gratefully acknowledges the support provided for this webinar by ExThera Medical.
Sean Phillip Barnett, MD
Nephrology / Critical Care, UTHSCSA / STX-VAMC
Dr. Sean Barnett is a Cardiorenal Intensivist. He studied Nephrology and Critical Care, and specializes in COVID-19, Heart Failure, ICU medicine and Extracorporeal Life Support. Over the years, he has published multiple pieces in various journals and recently presented at the American Society of Nephrology and CHEST (The American College of Chest Physicians) in their 2021 annual meetings. Most recently, he has been working on COVID-19 research and believes to have discovered part of the most significant pathology in the COVID-19 Cytokine Storm.
Lakhmir Chawla, MD
Adjunct Professor, Veterans Affairs Medical Center, San Diego, CA
Dr. Lakhmir (Mink) Chawla is Silver Creek Pharmaceutical’s Chief Medical Officer, and a Clinical Professor of Medicine at the UCSD Medical Center and Veterans Affairs Medical Center. Dr. Chawla was a Professor of Medicine at the George Washington University Medical Center in Washington, D.C. where he directed research efforts for the Division of Critical Care Medicine. He previously headed the Division of Intensive Care Medicine at the Washington DC Veterans Affairs Medical Center. With a focus on critical care and nephrology, Dr. Chawla has led and supported several grants and research projects centered on acute kidney injury, renal disease, extracorporeal therapies, shock, and sepsis.
No continuing education credits are offered for this session.
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Welcome to the webinar, Hope for Critically Ill COVID-19 Patients: Pathogen Hemofiltration - Latest Data & Clinical Experience: Part II.
Please proceed to download the slides, then view the webinar.
No continuing education credits are offered for this sponsored webinar.